drugset
drugset / Trial / NCT02355431

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

NCT02355431 ↗

Phase 2 Withdrawn Incyte Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if Itacitinib in combination with erlotinib is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB/Stage IV or recurrent whose tumors have EGFR activating mutations.

Timeline

Start
2014-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Itacitinib Small molecule — Oral
Background Erlotinib Small molecule 150 mg Oral

Indications

hematopoietic and lymphoid cell neoplasm non-small cell lung carcinoma